CAS 870483-87-7 | GW2580 | CAS Number 870483-87-7

200,000+ products from a single source!

sales@angenechem.com

Product Categories

Home > Other Building Blocks > 870483-87-7

870483-87-7 | GW2580

CAS No: 870483-87-7 Catalog No: AG0036CW MDL No:MFCD12024701

Product Description

Catalog Number:

AG0036CW

Chemical Name:

GW2580

CAS Number:

870483-87-7

Molecular Formula:

C20H22N4O3

Molecular Weight:

366.4137

MDL Number:

MFCD12024701

IUPAC Name:

5-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]pyrimidine-2,4-diamine

InChI:

InChI=1S/C20H22N4O3/c1-25-16-6-3-13(4-7-16)12-27-17-8-5-14(10-18(17)26-2)9-15-11-23-20(22)24-19(15)21/h3-8,10-11H,9,12H2,1-2H3,(H4,21,22,23,24)

InChI Key:

MYQAUKPBNJWPIE-UHFFFAOYSA-N

SMILES:

COc1cc(ccc1OCc1ccc(cc1)OC)Cc1cnc(nc1N)N

UNII:

SRV0JCF9LI

Properties

Complexity:

433

Compound Is Canonicalized:

Yes

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Exact Mass:

366.169g/mol

Formal Charge:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Isotope Atom Count:

Molecular Weight:

366.421g/mol

Monoisotopic Mass:

366.169g/mol

Rotatable Bond Count:

Topological Polar Surface Area:

106A^2

Undefined Atom Stereocenter Count:

Undefined Bond Stereocenter Count:

XLogP3:

2.6

Literature

Title	Journal
Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.	Brain : a journal of neurology 20160301
Identification of potent Yes1 kinase inhibitors using a library screening approach.	Bioorganic & medicinal chemistry letters 20130801
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.	The Biochemical journal 20130415
Regulation of microglial proliferation during chronic neurodegeneration.	The Journal of neuroscience : the official journal of the Society for Neuroscience 20130206
Role of cell cycle-associated proteins in microglial proliferation in the axotomized rat facial nucleus.	Glia 20120401
Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.	Journal of clinical immunology 20111201
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.	Nature biotechnology 20111101
Comprehensive analysis of kinase inhibitor selectivity.	Nature biotechnology 20111030
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.	European journal of medicinal chemistry 20110601
Macrophage-colony stimulating factor and interleukin-34 induce chemokines in human whole blood.	Cytokine 20101201
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.	Chemistry & biology 20101124
Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis.	The Journal of pathology 20100501
Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.	Blood 20100218
c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.	Arthritis research & therapy 20100101
Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats.	The Journal of pharmacology and experimental therapeutics 20080701
A quantitative analysis of kinase inhibitor selectivity.	Nature biotechnology 20080101
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	Proceedings of the National Academy of Sciences of the United States of America 20071218
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.	Proceedings of the National Academy of Sciences of the United States of America 20051101